It's all in the family: Multiple toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection

Philberta Y. Leung, Amy E B Packard, Mary Stenzel-Poore

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ischemic tolerance is a biological process that can be utilized to unlock the brain's own endogenous protection mechanisms and, as such, holds true promise for patients at risk of ischemic injury. Experimentally, preconditioning with various Toll-like receptor (TLR) agonists has now been demonstrated to successfully attenuate ischemic damage, partly through genomic reprogramming of the body's response to stroke. This treatment diminishes the inflammatory response to stroke and at the same time enhances the production of anti-inflammatory cytokines and neuroprotective mediators. This review discusses recent discoveries about the role of TLRs in preconditioning and ischemic tolerance.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalFuture Neurology
Volume4
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Toll-Like Receptors
Stroke
Biological Phenomena
Ischemic Preconditioning
Anti-Inflammatory Agents
Cytokines
Wounds and Injuries
Brain
Therapeutics
Neuroprotection

Keywords

  • Ischemic tolerance
  • Preconditioning
  • Stroke
  • Toll-like receptors

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

It's all in the family : Multiple toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection. / Leung, Philberta Y.; Packard, Amy E B; Stenzel-Poore, Mary.

In: Future Neurology, Vol. 4, No. 2, 2009, p. 201-208.

Research output: Contribution to journalArticle

@article{fa155b96a6244a0c8d4556e5ef0c242d,
title = "It's all in the family: Multiple toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection",
abstract = "Ischemic tolerance is a biological process that can be utilized to unlock the brain's own endogenous protection mechanisms and, as such, holds true promise for patients at risk of ischemic injury. Experimentally, preconditioning with various Toll-like receptor (TLR) agonists has now been demonstrated to successfully attenuate ischemic damage, partly through genomic reprogramming of the body's response to stroke. This treatment diminishes the inflammatory response to stroke and at the same time enhances the production of anti-inflammatory cytokines and neuroprotective mediators. This review discusses recent discoveries about the role of TLRs in preconditioning and ischemic tolerance.",
keywords = "Ischemic tolerance, Preconditioning, Stroke, Toll-like receptors",
author = "Leung, {Philberta Y.} and Packard, {Amy E B} and Mary Stenzel-Poore",
year = "2009",
doi = "10.2217/14796708.4.2.201",
language = "English (US)",
volume = "4",
pages = "201--208",
journal = "Future Neurology",
issn = "1479-6708",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - It's all in the family

T2 - Multiple toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection

AU - Leung, Philberta Y.

AU - Packard, Amy E B

AU - Stenzel-Poore, Mary

PY - 2009

Y1 - 2009

N2 - Ischemic tolerance is a biological process that can be utilized to unlock the brain's own endogenous protection mechanisms and, as such, holds true promise for patients at risk of ischemic injury. Experimentally, preconditioning with various Toll-like receptor (TLR) agonists has now been demonstrated to successfully attenuate ischemic damage, partly through genomic reprogramming of the body's response to stroke. This treatment diminishes the inflammatory response to stroke and at the same time enhances the production of anti-inflammatory cytokines and neuroprotective mediators. This review discusses recent discoveries about the role of TLRs in preconditioning and ischemic tolerance.

AB - Ischemic tolerance is a biological process that can be utilized to unlock the brain's own endogenous protection mechanisms and, as such, holds true promise for patients at risk of ischemic injury. Experimentally, preconditioning with various Toll-like receptor (TLR) agonists has now been demonstrated to successfully attenuate ischemic damage, partly through genomic reprogramming of the body's response to stroke. This treatment diminishes the inflammatory response to stroke and at the same time enhances the production of anti-inflammatory cytokines and neuroprotective mediators. This review discusses recent discoveries about the role of TLRs in preconditioning and ischemic tolerance.

KW - Ischemic tolerance

KW - Preconditioning

KW - Stroke

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=67149123473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67149123473&partnerID=8YFLogxK

U2 - 10.2217/14796708.4.2.201

DO - 10.2217/14796708.4.2.201

M3 - Article

AN - SCOPUS:67149123473

VL - 4

SP - 201

EP - 208

JO - Future Neurology

JF - Future Neurology

SN - 1479-6708

IS - 2

ER -